136 related articles for article (PubMed ID: 11569889)
1. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation.
Bubalo J; Seelig F; Karbowicz S; Maziarz RT
Biol Blood Marrow Transplant; 2001; 7(8):439-45. PubMed ID: 11569889
[TBL] [Abstract][Full Text] [Related]
2. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
4. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Tan M; Xu R; Seth R
Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
[TBL] [Abstract][Full Text] [Related]
5. Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation.
Fauser AA; Russ W; Bischoff M
Support Care Cancer; 1997 May; 5(3):219-22. PubMed ID: 9176968
[TBL] [Abstract][Full Text] [Related]
6. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Walsh T; Morris AK; Holle LM; Callander N; Bradshaw P; Valley AW; Clark G; Freytes CO
Bone Marrow Transplant; 2004 Dec; 34(11):963-8. PubMed ID: 15489869
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Bey P; Wilkinson PM; Resbeut M; Bourdin S; Le Floch O; Hahne W; Claverie N
Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF
Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466
[TBL] [Abstract][Full Text] [Related]
11. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
[TBL] [Abstract][Full Text] [Related]
13. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
Kovac AL; Scuderi PE; Boerner TF; Chelly JE; Goldberg ME; Hantler CB; Hahne WF; Brown RA
Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Fauser AA; Duclos B; Chemaissani A; Del Favero A; Cognetti F; Diaz-Rubio E; Cortes-Funes H; Conte PF; Dressler H
Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
[TBL] [Abstract][Full Text] [Related]
15. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
Korttila K; Clergue F; Leeser J; Feiss P; Olthoff D; Payeur-Michel C; Wessel P; Nave S; Hahne W; Brown R
Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
[TBL] [Abstract][Full Text] [Related]
17. Patient outcomes after therapeutic interchange of dolasetron for granisetron.
Steiner MA; Yorgason RZ; Vermeulen LC; Theisen J
Am J Health Syst Pharm; 2003 May; 60(10):1023-8. PubMed ID: 12789874
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
[TBL] [Abstract][Full Text] [Related]
19. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery.
Graczyk SG; McKenzie R; Kallar S; Hickok CB; Melson T; Morrill B; Hahne WF; Brown RA
Anesth Analg; 1997 Feb; 84(2):325-30. PubMed ID: 9024022
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
